Skip to Main Content
Contribute Try STAT+ Today

The number of people treated with approved gene therapies and gene-modified cell therapies like CAR-T cancer treatments in the United States and Europe has reached more than 4,500, according to an estimate from the Alliance for Regenerative Medicine.

The figure comes from the trade group’s 2019 annual report, released Thursday. The alliance also reported that 1,066 clinical trials for gene therapies, cell therapies, and tissue engineering products were underway at the end of 2019. Regenerative medicine trials have room for more than 60,000 patients to enroll around the world.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.